In our cohort, we found that patients with KRAS G12R mutant PDA had significantly longer survival rates compared to those with non-G12R KRAS mutant tumors, possibly due to deficient PI3K/AKT/mTOR signaling. The gene discussed is AKT1; the disease is Patent ductus arteriosus.